Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: engnw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Holdings Inc. (NASDAQ:ENGN, ENGNW) filed an 8-K covering board and management changes effective July 7-8, 2025.
- Director resignation: Jasper Bos resigned from the Board on July 7, 2025; the company states there was no disagreement regarding operations, policies or practices.
- Board appointments: The Board appointed Philip Astley-Sparke to fill the vacancy as of July 8, 2025, for the remainder of Bos’s term expiring at the 2026 AGM. The Board then increased its size from seven to nine and named William Grossman and Michael Heffernan as additional directors, each serving until the next AGM.
- Compensation & indemnification: All three new directors will participate in the company’s standard independent-director compensation plan and enter into indemnification agreements identical to those filed as Exhibits 10.17 and 10.18 to the 2024 Annual Report.
- Committee assignments: Not yet determined for the new directors.
- Management promotions (Reg FD disclosure): A July 8 press release (Exhibit 99.1) announced promotions of Matthew Boyd to Chief Regulatory Officer and Jill Buck to Chief Development Officer.
No transactions requiring disclosure under Item 404(a) were reported. The information furnished under Item 7.01 is expressly not deemed “filed” under the Exchange Act.